Paediatric Intensive Care Unit, Birmingham Children's Hospital, Birmingham, UK.
Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Perfusion. 2020 Nov;35(8):802-805. doi: 10.1177/0267659120914141. Epub 2020 May 13.
There is a need for a universal risk-adjustment model that may be used regardless of the indication and nature of neonatal or paediatric extracorporeal membrane oxygenation support. The 'paediatric extracorporeal membrane oxygenation prediction' model appeared to be a promising candidate but required external validation.
We performed a validation study using institutional database of extracorporeal membrane oxygenation patients (2008-2019). We used the published paediatric extracorporeal membrane oxygenation prediction score calculator to derive estimated mortality based on the model in this cohort of patients in our institutional database. We used standardized mortality ratio, area under the receiver operating characteristic curve and Hosmer-Lemeshow goodness-of-fit test in 10 deciles to assess model performance.
We analysed 154 extracorporeal membrane oxygenation episodes in 150 patients. About 53% of the patients were full term (age ⩽30 days and gestation at birth ⩾37 weeks) neonates. The commonest category of extracorporeal membrane oxygenation support was cardiac (42%). The overall in-paediatric intensive care unit mortality was 37% (57/154) and the in-hospital mortality was 42% (64/154). Distribution of estimated mortality risk was similar to the derivation study. The calculated standardized mortality ratio was 0.81 based on the paediatric extracorporeal membrane oxygenation prediction model of risk-adjustment. The area under the receiver operating characteristic curve was 0.55 (0.45-0.64) and Hosmer-Lemeshow-test p value <0.001 was unable to support goodness-of-fit.
This small single-centre study with a small number of events was unable to validate the paediatric extracorporeal membrane oxygenation prediction-model of risk-adjustment. Although this remains the most promising of all the available models, further validation in larger data sets and/or refinement may be required before widespread use.
需要一种通用的风险调整模型,无论新生儿或儿科体外膜肺氧合支持的适应证和性质如何,都可以使用该模型。“儿科体外膜肺氧合预测”模型似乎是一个很有前途的候选模型,但需要外部验证。
我们使用体外膜肺氧合患者的机构数据库(2008-2019 年)进行了验证研究。我们使用已发表的儿科体外膜肺氧合预测评分计算器,根据模型在本机构数据库中患者队列中的数据,计算出估计死亡率。我们使用标准化死亡率比、受试者工作特征曲线下面积和 Hosmer-Lemeshow 拟合优度检验在 10 个十分位数中评估模型性能。
我们分析了 150 例患者的 154 例体外膜肺氧合事件。约 53%的患者是足月(年龄≤30 天,出生时胎龄≥37 周)新生儿。体外膜肺氧合支持最常见的类别是心脏(42%)。儿科重症监护病房的总院内死亡率为 37%(57/154),院内死亡率为 42%(64/154)。估计死亡率风险的分布与推导研究相似。基于儿科体外膜肺氧合风险调整预测模型,计算出的标准化死亡率比为 0.81。受试者工作特征曲线下面积为 0.55(0.45-0.64),Hosmer-Lemeshow 检验 p 值<0.001,无法支持拟合优度。
这项小型单中心研究事件数量较少,无法验证儿科体外膜肺氧合预测风险调整模型。尽管这仍然是所有现有模型中最有前途的模型,但在广泛应用之前,可能需要在更大的数据集和/或改进中进行进一步验证。